Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial


ACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women ACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women

Read more:
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial

Related Posts